Ex vivo inhibition of NF-κB signaling in alloreactive T-cells prevents graft-versus-host disease

American Journal of Transplantation

Volumn 9, Issue 3, 2009, Pages 452-462

  O'Shaughnessy, M J ^a   Vogtenhuber, C ^a   Sun, K ^b   Sitcheran, R ^c   Baldwin, A S ^c   Murphy, W J ^b   Dang, L ^d   Jaffee, B ^d   Palmer, E ^e   Serody, J S ^c   Blazar, B R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Alloantigens; Allogeneic; Allograft tolreance; Alloreactive T cells; Allorecognition; Allotransplantation; Bone marrow transplantation; CD4+ T cells; Donor T cell; Graft versus host disease; Immune tolerance; Nuclear factor kappa B (NF B); T cell

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ALLOANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GRAFT VS HOST DISEASE; HETEROCYCLIC COMPOUNDS, 3-RING; ISOANTIGENS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MODELS, IMMUNOLOGICAL; NF-KAPPA B; PYRIDINES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 60649107893     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02533.x     Document Type: Article

References (41)

1. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995 86 : 1228 1234.
2. Davies SM, Shu XO, Blazar BR et al. Unrelated donor bone marrow transplantation: Influence of HLA A and B incompatibility on outcome. Blood 1995 86 : 1636 1642.
3. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000 96 : 2062 2068.
4. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998 92 : 2303 2314.
5. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001 98 : 3192 3204.
6. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: Current results and future directions. Bone Marrow Transplant 1988 3 : 185 192.
7. Martin PJ, Hansen JA, Torok-Storb B et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988 3 : 445 456.
8. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999 163 : 3684 3691.
9. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T-cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Investigat 1998 102 : 473 482.
10. Gribben JG, Guinan EC, Boussiotis VA et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996 87 : 4887 4893.
11. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004 103 : 1158 1165.
12. Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004 101 : 8120 8125.
13. Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T-cells in an H-2 haplotype disparate mouse combination. Blood 1994 83 : 288 298.
14. Solomon SR, Mielke S, Savani BN et al. Selective depletion of alloreactive donor lymphocytes: A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005 106 : 1123 1129.
15. Guinan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999 340 : 1704 1714.
16. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T-cells. J Immunol 1991 147 : 2461 2466.
17. DeSilva DR, Urdahl KB, Jenkins MK. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991 147 : 3261 3267.
18. Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992 13 : 69 73.
19. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987 165 : 302 319.
20. Ghosh P, Tan TH, Rice NR, Sica A, Young HA. The interleukin 2 CD28-responsive complex contains at least three members of the NF-κB family: c-Rel, p50, and p65. Proc Natl Acad Sci USA 1993 90 : 1696 1700.
21. Wang D, Matsumoto R, You Y et al. CD3/CD28 costimulation-induced NF-κB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IκB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 2004 24 : 164 171.
22. Wang D, You Y, Case SM et al. A requirement for CARMA1 in TCR-induced NF-κB activation. Nature Immunol 2002 3 : 830 835.
23. Ruland J, Duncan GS, Elia A et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 2001 104 : 33 42.
24. Coudronniere N, Villalba M, Englund N, Altman A. NF-κB activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Nat Acad Sci USA 2000 97 : 3394 3399.
25. Lin X, O'Mahony A, Mu Y, Geleziunas R, Greene WC. Protein kinase C-theta participates in NF-κB activation induced by CD3-CD28 costimulation through selective activation of IκB kinase beta. Mol Cell Biol 2000 20 : 2933 2940.
26. Sun Z, Arendt CW, Ellmeier W et al. PKC-theta is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 2000 404 : 402 407.
27. Janssen R, van Wengen A, Hoeve MA et al. The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J Exp Med 2004 200 : 559 568.
28. Doffinger R, Smahi A, Bessia C et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet 2001 27 : 277 285.
29. Courtois G, Smahi A, Reichenbach J et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 2003 112 : 1108 1115.
30. Hideshima T, Chauhan D, Richardson P et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002 277 : 16639 16647.
31. Chen ZM, O'Shaughnessy MJ, Gramaglia I et al. IL-10 and TGF-beta induce alloreactive CD4+CD25- T-cells to acquire regulatory cell function. Blood 2003 101 : 5076 5083.
32. O'Shaughnessy MJ, Chen ZM, Gramaglia I et al. Elevation of intracellular cyclic AMP in alloreactive CD4(+) T-cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivo. Biol Blood Marrow Transplant 2007 13 : 530 542.
33. Brice GT, Riley JL, Villinger F et al. Development of an animal model for autotransfusion therapy: In vitro characterization and analysis of anti-CD3/CD28 expanded cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998 19 : 210 220.
34. Mayo MW, Norris JL, Baldwin AS. Ras regulation of NF-κB and apoptosis. Meth Enzymol 2001 333 : 73 87.
35. Taube M, Svensson L, Carlsten H. T lymphocytes are not the target for estradiol-mediated suppression of DTH in reconstituted female severe combined immunodeficient (SCID) mice. Clin Exp Immunol 1998 114 : 147 153.
36. Saemann MD, Kelemen P, Bohmig GA, Horl WH, Zlabinger GJ. Hyporesponsiveness in alloreactive T-cells by NF-κB inhibitor-treated dendritic cells: Resistance to calcineurin inhibition. Am J Transplant 2004 4 : 1448 1458.
37. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001 193 : 1311 1318.
38. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nature Med 2004 10 : 87 92.
39. Sun K, Wilkins DE, Anver MR et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005 106 : 3293 3299.
40. Sun K, Sayers TJ, Welniak LA, Murphy WJ. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008 112 : 1522 1529.
41. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-κB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood 2006 107 : 827 834.